Bronwyn Le Grice Email & Phone Number

Melbourne, Vic, Au

Melbourne, Vic, Au

ANDHealth is Australia’s only organisation dedicated to and specialised in the acceleration of commercialisation for digital health companies. It has a proven track record of accelerating the global scale-up of high growth potential companies in digital health creating jobs, growing revenue, raising capital, undertaking clinical trials and impacting hundreds of thousands of patients globally.The ANDHealth model is globally unique and leverages a non-profit, non-equity taking framework and Australia's broadest and deepest database of emerging digital health companies, having engaged with over 500 companies since our incorporation in 2017.ANDHealth delivers the highly respected ANDHealth+ program and manages the ANDHealth Digital Health Accelerator Fund. ANDHealth+ is the leading digital health commercialisation program in Australia with 90% of cohort companies in the pilot program (10 companies in total) going on to raise >$60M to date.ANDHealth+ is designed for proof-of-concept stage, evidence-based digital health SMEs which act to treat, diagnose, cure, mitigate and/or prevent disease or other conditions and is supported by the Australian Government under the Medical Research Future Fund Early Stage Translation and Commercialisation Support Program.

Carlsbad, California, Us

Carlsbad, California, Us

Carlsbad, California, Us

Carlsbad, California, Us

Canberra, Act, Au

The NHMRC is the nation’s leading body supporting excellent health and medical research toimprove health outcomes for all Australians. It provides the foundation for Australia’smedical research capability, funding the best research and researchers, ensuring consistenthealth standards and advising on ethical issues in health. The Council’s role is to ensure thatrobust expert advice reflecting a wide range of perspectives is provided to the NHMRC ChiefExecutive Officer, Professor Anne Kelso AO, to support these functions.

Fidere: Latin - to trust in, to have confidence in...Fidere Group provides business strategy and management services to high growth technology and health technology companies which help them to better interact with new and potential investors and the capital markets. Services include Corporate Strategy & Development, Transaction Project Management, Corporate Governance, IR/Communications and General Management. Projects include:- Adherium (ASX:ADR) IPO, including management of NZ$2m pre-IPO convertible note, preparation of business plan and positioning, DDC participation & drafting of prospectus, resulting in a A$35m twice oversubscribed capital raising, successful listing and ongoing performance at 25%+ over and above the offer price. - Member of executive team responsible for negotiating first-in-class global commercial supply agreement with a multinational pharmaceutical company for digital technology to be supplied alongside a blockbuster respiratory medication. - Reverse acquisition of Rex Bionics (NZ) Limited by Union Medtech (ISDX.UMT) and associated AIM IPO (£10M), including management and coordination of all due diligence, legal and accounting suppliers, pre-IPO capital raising (~£1M) and executive management of the NZ target. The newly merged entity Rex Bionics Plc (AIM.RXB) was admitted to AIM May 8, 2014 with a market cap of £25.7 million.- Strategic advice and support for a fast-growth, online ticketing provider including facilitating shareholder buy-out of founding business partner and subsequent part-acquisition by an international industry player for a 10x multiple.- Development of an integrated communications strategy to support patient recruitment and engagement in a global Phase III clinical trial for ovarian cancer, including in-depth retrospective research into online communications by patients and their carers, and the development of a strategy on which to appropriately engage with and support those target audiences.

San Diego, California, Us

Imagion Biosystems (ASX.IBX) is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSenseTM technology, the company has the potential to optimize patient care and reduce mortality rates across various cancer indications. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

PetHomeStay is an online community to provide petcare for pet owners in their local community. An alternative to traditional boarding and minding services, PetHomeStay allows pet owners to find people in their community who are willing and able to look after their pet, be it overnight stays, daycare or other services.PetHomeStay is Australia's only peer to peer pet care marketplace offering full insurance coverage to both hosts (public liability) and pets (accident & emergency).- Business development, planning and governance leadership.- Capital raising strategy and support of CEO in developing necessary investor documentation.- Investor relations, liaison with venture capital firms.

Melbourne, Au

Bioscience Managers (formerly IB Managers) is an international Funds Management firm, led by industry veteran Jeremy Curnock Cook and headquartered in the PhillipCapital Melbourne office. With more than 30 years’ experience in biosciences funds management, a multi-disciplinary, international team of industry leaders and a highly selective investment philosophy, Bioscience Managers is a leading bioscience fund manager in Australasia.Bioscience Managers consistently deliver exceptional returns to investors, whilst supporting companies which improve health outcomes and quality of life. The firm has wound up it's first fund, the Australian Bioscience Fund I, which delivered 24.7% IRR net of management fees to its investors. The Asia Pacific Healthcare Fund II is currently under management and will close to new investors in September 2014.- Corporate development activities relating to identifying and approaching new Limited Partners (LP’s) to increase funds under management. - Marketing roadshows including presentation of fund products to potential Limited Partners’s - Member of the investment and due diligence team - Media relations and corporate communications- Management of portfolio companies & portfolio including project management of shareholder action, on-going liaison with company CEO’s and strategic support especially in the areas of marketing, branding, corporate and government affairs and investor relations programs.- Implementation of cloud based tools to allow for global team collaboration during the investment process.

Melbourne, Victoria, Au

Adherium Ltd (formerly Nexus6 Ltd) is a digital health company focused on digital health technologies which address sub-optimal medication use in chronic disease, was a privately owned NZ based company, which listed on the ASX via an Australian parent entity in August 2015.- Project leader of Adherium (ASX:ADR) IPO, including management of NZ$2m pre-IPO convertible note, preparation of business plan and positioning, DDC participation & drafting of prospectus, resulting in a A$35m twice oversubscribed capital raising, successful listing and ongoing performance at 25%+ over and above the offer price. - Member of executive team responsible for negotiating first-in-class global commercial supply agreement with a multinational pharmaceutical company for digital technology to be supplied alongside a blockbuster respiratory medication. - ASX Compliance Officer, Company Secretary & lead contact for investors and corporate advisors. Responsible for Internal Audit & Risk Management. - Responsible for all Investor relations activities, including preparation and drafting of announcements, annual and half yearly reports, participation in road shows, quarterly calls and ongoing shareholder management.

NZBIO is a non-profit incorporated society advocating for the bio-based industries in New Zealand as a driver of innovation and economic growth.Key projects included:- Publication of key policy documents including “Driving Economic Growth Through Bio-Based Industries”; “The Importance of New Zealand’s Human Therapeutics Sector to Future Economic Growth”; and “New Zealand Biotechnology Industry Growth Report”.- Management & execution of the NZ delegation to Bio (US). Deal flow from surveyed participants was estimated at up to NZD$500 million.- Development and execution of the annual NZBIO conference for ~500 industry attendees each year, delivering profits and improving international investor attendance.- Broadened the scope of NZBIO’s national reach through securing of affiliate agreements with NZ Venture Capital Association, NZ Bioenergy Association, NZ Association for Clinical Research and NZ Medical Technology Association.- Successfully expanded NZBIO’s international partner network to 10 Asia Pacific nations and the United Kingdom.

Master'S Degree, Commercial Law

Prof Cert Commercialisation, Strategic Business Planning For Commercialisation

B.Com, Marketing, General Management, Business Law, Human Resources